RAPT Therapeutics CEO Brian Wong will present at the J.P. Morgan Healthcare Conference on January 14, 2026.
Quiver AI Summary
RAPT Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in therapies for inflammatory and immunological diseases, announced that its CEO, Dr. Brian Wong, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 2:15 p.m. Pacific Time. The presentation will be accessible via a live webcast on RAPT's website, where an archived recording will also be available afterward. RAPT Therapeutics focuses on leveraging its expertise in immunology to develop innovative treatments aimed at modulating immune responses related to various diseases.
Potential Positives
- RAPT Therapeutics is participating in the prestigious 44th Annual J.P. Morgan Healthcare Conference, indicating strong market presence and visibility in the biopharmaceutical sector.
- The presentation by the CEO, Brian Wong, highlights the company’s commitment to transparency and engagement with investors and stakeholders.
- The focus on novel therapies for inflammatory and immunological diseases positions RAPT as an innovative player in a critical area of healthcare, potentially attracting interest from investors and partners.
Potential Negatives
- None
FAQ
What is RAPT Therapeutics known for?
RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on therapies for inflammatory and immunological diseases.
When will RAPT Therapeutics present at the J.P. Morgan Healthcare Conference?
RAPT Therapeutics will present on January 14, 2026, at 2:15 p.m. Pacific Time.
Where can I access the RAPT Therapeutics presentation?
The live webcast and archived recording will be available on the RAPT Therapeutics website.
Who is the CEO of RAPT Therapeutics?
Brian Wong, M.D., Ph.D. is the President and Chief Executive Officer of RAPT Therapeutics.
How can I contact RAPT Therapeutics for investor inquiries?
For investor inquiries, contact Sylvia Wheeler at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RAPT Hedge Fund Activity
We have seen 35 institutional investors add shares of $RAPT stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MEDICXI VENTURES MANAGEMENT (JERSEY) LTD added 2,794,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $72,057,260
- COLUMN GROUP LLC removed 1,162,538 shares (-87.5%) from their portfolio in Q3 2025, for an estimated $29,981,855
- BVF INC/IL removed 1,154,692 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $29,779,506
- BOONE CAPITAL MANAGEMENT LLC added 782,461 shares (+inf%) to their portfolio in Q3 2025, for an estimated $20,179,669
- IKARIAN CAPITAL, LLC added 615,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $15,860,850
- SIREN, L.L.C. added 580,466 shares (+inf%) to their portfolio in Q3 2025, for an estimated $14,970,218
- ORBIMED ADVISORS LLC removed 555,288 shares (-33.8%) from their portfolio in Q3 2025, for an estimated $14,320,877
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RAPT Analyst Ratings
Wall Street analysts have issued reports on $RAPT in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 12/18/2025
- Barclays issued a "Overweight" rating on 11/07/2025
- Wells Fargo issued a "Overweight" rating on 11/03/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/27/2025
- Guggenheim issued a "Buy" rating on 10/27/2025
- Clear Street issued a "Buy" rating on 10/21/2025
- Leerink Partners issued a "Outperform" rating on 09/26/2025
To track analyst ratings and price targets for $RAPT, check out Quiver Quantitative's $RAPT forecast page.
$RAPT Price Targets
Multiple analysts have issued price targets for $RAPT recently. We have seen 9 analysts offer price targets for $RAPT in the last 6 months, with a median target of $57.0.
Here are some recent targets:
- Anupam Rama from JP Morgan set a target price of $57.0 on 11/12/2025
- Etzer Darout from Barclays set a target price of $56.0 on 11/07/2025
- Yanan Zhu from Wells Fargo set a target price of $72.0 on 11/03/2025
- Yatin Suneja from Guggenheim set a target price of $70.0 on 10/27/2025
- Emily Bodnar from HC Wainwright & Co. set a target price of $72.0 on 10/27/2025
- Kaveri Pohlman from Clear Street set a target price of $60.0 on 10/21/2025
- Thomas Smith from Leerink Partners set a target price of $37.0 on 09/26/2025
Full Release
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 44 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pacific Time.
To access the live webcast or subsequent archived recording of the presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations .
About RAPT Therapeutics, Inc.
RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases.
RAPT Investor Contact:
Sylvia Wheeler
[email protected]
RAPT Media Contact:
Aljanae Reynolds
[email protected]
